Loading
JMT101 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.
JMT101 is a monoclonal antibody developed by Shanghai JMT-Bio. Its target is EGFR (the sponsor names EGFR). The sponsor states: JMT101 is a recombinant humanised anti-EGFR monoclonal antibody, given intravenously (6 mg/kg every two weeks) in combination with osimertinib versus osimertinib alone in EGFR-mutant non-small cell lung cancer. ClinicalTrials.gov describes the intervention as: JMT101 is a recombinant humanized anti-EGFR monoclonal antibody. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06735391 (A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations), in non-small-cell lung cancer. The largest, NCT06735391, plans to enrol 516 participants with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
JMT101 is a recombinant humanised anti-EGFR monoclonal antibody, given intravenously (6 mg/kg every two weeks) in combination with osimertinib versus osimertinib alone in EGFR-mutant non-small cell lung cancer. Connects to EGFR.
1.JMT101 binds EGFR.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JMT101" OR ABSTRACT:"JMT101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JMT101, not a curated reading list.
Shares Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer, CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer and the tag pipeline.
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.